AMLX Stock: Price, Earnings History and SEC Filings
Amylyx Pharmaceuticals, Inc. (AMLX) last traded at $28.86, up 0.63% on the latest session and down 0.8% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.39 against an analyst estimate of $-0.36, a miss of 8.3%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
AMLX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $-0.39 | $-0.36 | -8.33% |
| Mar 2026 | May 7, 2026 | $-0.37 | $-0.34 | -8.82% |
| Dec 2025 | Mar 3, 2026 | $-0.30 | $-0.31 | +3.23% |
| Sep 2025 | Nov 6, 2025 | $-0.37 | $-0.43 | +13.95% |
AMLX beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
How AMLX reacts to earnings
Across its last 8 earnings releases, AMLX moved 5.7% on average the next session, in either direction. It rose after 3 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-06 | Before open | +10.71% |
| 2026-05-07 | Before open | -5.35% |
| 2026-03-03 | Before open | -7.78% |
| 2025-11-06 | Before open | -5.89% |
| 2025-08-07 | Before open | -4.27% |
| 2025-05-08 | Before open | -5.95% |
| 2025-03-04 | Before open | +0.33% |
| 2024-11-07 | Before open | +5.14% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
AMLX financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $0 | -$145M | -$123M | – | $-1.53 |
| 2024 | $87M | -$302M | -$168M | -345.4% | $-4.43 |
| 2023 | $381M | $49M | $11M | 12.9% | $0.70 |
| 2022 | $22M | -$198M | -$182M | -892.4% | $-3.39 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for AMLX
- 8-K · Sep 8, 2026Material agreement
- 8-K · Aug 20, 2026Material agreement, Financial statements and exhibits
- 424B5 · Aug 20, 2026
- 424B5 · Aug 18, 2026
- 8-K · Aug 18, 2026Other events, Financial statements and exhibits
- 8-K · Aug 18, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 10-Q · Aug 6, 2026
- 8-K · Aug 6, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 4, 2026Shareholder vote
- 10-Q · May 7, 2026
Insider filing activity
AMLX insiders filed 12 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
AMLX news
- Can Corcept Therapeutics Stock Rally 40% After This Dip?Oct 26, 2026 · trefis.com
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc. (AMLX) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.